Existing Drugs Targeting Genes of Hereditary Pain Syndromes as Candidates for Analgesic Repurposing: An AI-Facilitated Computational Knowledge Discovery Analysis

Background/Objectives: Over the last few decades, hereditary syndromes with extreme pain phenotypes have guided the discovery of analgesic drugs. We hypothesized that genes of hereditary syndromes with altered pain perception, not necessarily the extreme phenotypes grouped as hereditary sensory and autonomic neuropathies, could also point to existing drugs with unrecognized analgesic properties via known interactions with syndrome-relevant gene products. Methods: Phenotypes with altered pain mentions were retrieved from the Online Mendelian Inheritance in Man (OMIM) database, and their genes were linked to targets of approved and investigational drugs in DrugBank. The 3662 PubMed records for the 169 drugs without pain annotation, of which 3237 remained after rule-based exclusions, were screened on title and abstract, assisted by a large language model with human verification of positive and inconclusive findings. Results: Eighty qualifying phenotypes were found, annotated with 81 genes, of which 22 were targets of 201 existing drugs. DrugBank mentioned pain or analgesia for 32 drugs (15.9%). Of the other 169 drugs, 51 (30.2%) had published reports of an analgesic or antinociceptive effect without explicit database annotation, including oxcarbazepine, lacosamide, and memantine. Published evidence included human data for 15 drugs and only preclinical data for 36 drugs, while for 73 drugs no record was retrieved. Conclusions: The main result of this analysis is a list of 169 drugs that target these genes but are not labeled as analgesics. Given the limited options for pain therapy, this AI-assisted, knowledge-based framework seems a feasible way to select candidates for expanding the class of analgesics through drug repurposing.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-11-20
DOI
https://doi.org/10.3390/ph19111854
Primary Topic
Pain Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Existing Drugs Targeting Genes of Hereditary Pain Syndromes as Candidates for Analgesic Repurposing: An AI-Facilitated Computational Knowledge Discovery Analysis

Jörn Lötsch, Dario Kringel, André Himmelspach
1 links
Pharmaceuticals
Pain Mechanisms and Treatments
article

Existing Drugs Targeting Genes of Hereditary Pain Syndromes as Candidates for Analgesic Repurposing: An AI-Facilitated Computational Knowledge Discovery Analysis

Jörn Lötsch, Dario Kringel, André Himmelspach
article en

Abstract

Background/Objectives: Over the last few decades, hereditary syndromes with extreme pain phenotypes have guided the discovery of analgesic drugs. We hypothesized that genes of hereditary syndromes with altered pain perception, not necessarily the extreme phenotypes grouped as hereditary sensory and autonomic neuropathies, could also point to existing drugs with unrecognized analgesic properties via known interactions with syndrome-relevant gene products. Methods: Phenotypes with altered pain mentions were retrieved from the Online Mendelian Inheritance in Man (OMIM) database, and their genes were linked to targets of approved and investigational drugs in DrugBank. The 3662 PubMed records for the 169 drugs without pain annotation, of which 3237 remained after rule-based exclusions, were screened on title and abstract, assisted by a large language model with human verification of positive and inconclusive findings. Results: Eighty qualifying phenotypes were found, annotated with 81 genes, of which 22 were targets of 201 existing drugs. DrugBank mentioned pain or analgesia for 32 drugs (15.9%). Of the other 169 drugs, 51 (30.2%) had published reports of an analgesic or antinociceptive effect without explicit database annotation, including oxcarbazepine, lacosamide, and memantine. Published evidence included human data for 15 drugs and only preclinical data for 36 drugs, while for 73 drugs no record was retrieved. Conclusions: The main result of this analysis is a list of 169 drugs that target these genes but are not labeled as analgesics. Given the limited options for pain therapy, this AI-assisted, knowledge-based framework seems a feasible way to select candidates for expanding the class of analgesics through drug repurposing.

PharmaceuticalsVol. 19(11)
Goethe University Frankfurt (DE), University of Helsinki (FI), Fraunhofer Institute for Translational Medicine and Pharmacology (DE)
Good health and well-being
Pain Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon